142 related articles for article (PubMed ID: 35733944)
1. Practical Considerations in the Administration of Aducanumab for the Neurologist.
Coerver K; Yu MM; D'Abreu A; Wasserman M; Nair KV
Neurol Clin Pract; 2022 Apr; 12(2):169-175. PubMed ID: 35733944
[TBL] [Abstract][Full Text] [Related]
2. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
DiStefano MJ; Alexander GC; Polsky D; Anderson GF
J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
[TBL] [Abstract][Full Text] [Related]
3. Making the Case for Accelerated Withdrawal of Aducanumab.
Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
[TBL] [Abstract][Full Text] [Related]
4. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
5. Is Aducanumab for LMICs? Promises and Challenges.
Gunawardena IPC; Retinasamy T; Shaikh MF
Brain Sci; 2021 Nov; 11(11):. PubMed ID: 34827546
[TBL] [Abstract][Full Text] [Related]
6. Making the Case for the Accelerated Withdrawal of Aducanumab.
Whitehouse PJ; Saini V
J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
[TBL] [Abstract][Full Text] [Related]
7. An insider's perspective on FDA approval of aducanumab.
Wang Y
Alzheimers Dement (N Y); 2023; 9(2):e12382. PubMed ID: 37215506
[TBL] [Abstract][Full Text] [Related]
8. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.
Heidebrink JL; Paulson HL
Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515
[TBL] [Abstract][Full Text] [Related]
9. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.
Esang M; Gupta M
Cureus; 2021 Aug; 13(8):e17591. PubMed ID: 34646644
[TBL] [Abstract][Full Text] [Related]
10. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
[TBL] [Abstract][Full Text] [Related]
11. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
12. Aducanumab: First Approval.
Dhillon S
Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
[TBL] [Abstract][Full Text] [Related]
13. Aduhelm, the Newly Approved Medication for Alzheimer Disease: What Epidemiologists Can Learn and What Epidemiology Can Offer.
Glymour MM; Weuve J; Dufouil C; Mayeda ER
Am J Epidemiol; 2022 Jul; 191(8):1347-1351. PubMed ID: 35388413
[TBL] [Abstract][Full Text] [Related]
14. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
15. A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease.
Yeo-Teh NSL; Tang BL
Sci Eng Ethics; 2023 Jan; 29(1):2. PubMed ID: 36625928
[TBL] [Abstract][Full Text] [Related]
16. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
17. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
Knopman DS; Jones DT; Greicius MD
Alzheimers Dement; 2021 Apr; 17(4):696-701. PubMed ID: 33135381
[TBL] [Abstract][Full Text] [Related]
18. Aducanumab for Alzheimer's disease: A regulatory perspective.
Nisticò R; Borg JJ
Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
Høilund-Carlsen PF; Alavi A
J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
